Active, not recruitingPhase 2NCT04172259

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Wen Xia, MD
SunYat-sen University Cancer Center
Intervention
Doxorubicin liposome(drug)
Enrollment
156 target
Eligibility
18-70 years · All sexes
Timeline
2019 – 2026

Study locations (1)

Collaborators

First Affiliated Hospital, Sun Yat-Sen University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04172259 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis →

← Back to all trials